Searchable abstracts of presentations at key conferences in endocrinology

ea0056p761 | Neuroendocrinology | ECE2018

Recurrence of hyperprolactinemia after dopamine agonists withdrawal

Contreras Pascual Cristina , Gonzalez Lazaro Paloma , Silva Fernandez Julia , Gomez Garcia Ines , Maria Torres Arroyo Belvis , del Val Zaballos Florentino , Javier Gomez Alfonso Francisco , Garcia Manzanares Vazquez Alvaro

Introduction: Prolactinomas are the most common tumors among functional pituitary adenomas and they constitute 40% of all pituitary tumors. Dopamine agonists (DA) are considered the primary treatment of prolactinoma. DA can lead to complete remission (including eradicacion of the tumor), allowing discotinuation of treatment. So far, there aren’t clinical criteria with sufficient predictive value for long-term remission.Objective: To assess the effec...